September 4, 2007

Now Moved In!

Posted by Eric at 4:55 pm | Category: Biology, Links, Personal, Pharmaceuticals

I am now moved in to my new room in graduate school. Classes have yet to start, but the weather is nice, the rooms are spacious, and the campus is very beautiful. It’s a bit weird to settle into a new campus this fall instead of returning to the old undergraduate campus, but I’m very excited about what’s to come. I’m also nervous that I’ve gotten soft during the summer, so I’m currently reviewing a bit of genetics, but in the meantime, I stumbled upon this interesting article on treating HIV by raising its mutation rate.

This is an interesting idea, since one would normally think that raising mutation rates on an organism would just increase the opportunities for it to become more virulent, more resistant, etc. But HIV is a pretty high-mutation rate virus already (any specific one letter mutation will arise more than 20,000 times per day); by the estimate of Martin Nowak, it’s mutation rate is currently the highest possible rate that allows for efficient adaptation and natural selection, in that if the mutation rate were lower, the virus would not adapt as quickly to adverse conditions (e.g. drugs), and if the mutation rate were higher, the virus would mutate so much that it would find it difficult to maintain any beneficial mutations. It’s at the cusp, the so-called “error threshold” (which is roughly the reciprocal of the genome length). So, by raising the mutation rate of HIV even higher, one could tip HIV over the error threshold and make the HIV quasi-species unstable enough to hamper its spread.

I only wonder, however, what kind of cancerous havoc it might raise in the human body. The drug doesn’t look flat enough to incorporate into anything but the most error-prone of DNA polymerases (e.g. HIV reverse transcriptase), but still, clinical study might show high rates of skin cancer and congenital defects for fetuses. The lack of a double bond on the major groove side of the nucleoside should prevent too many cycloadducts from forming with UV light, but then again, I’m no expert in heterocycle photochemistry, seeing as almost all the heterocycle-forming reactions I’ve ever tried to do ended with awful black tar on the bottom of my tiny flask.

9 Responses to “Now Moved In!”

  1. Ben Says:
    September 4th, 2007 at 6:41 pm

    1. You’re always worried you’ve gone soft. Just chill out one of these days. Grad school should be a chance to focus on studying what you want to study which should be fun, not “oh my god I’m falling behind” — think like that, and you’ll have a miserable time there.

    2. The drug idea is an interesting concept — but the collateral damage seems pretty horrible to me. “Yay! You’re cured of AIDs, but I’ve just given you horrible horrible metastatic cancer…”

    3. Hmmm… a sugar drug? Gee, that sounds like a great idea…

    4. This may be like the opposite of AZT — a crap drug for HIV, but an excellent drug for cancer

  2. Talking About Chemistry? Now.. FSU researchers use photochemistry to.. » Science Discoveries . net Says:
    September 5th, 2007 at 12:30 pm

    [...] Now Moved In! I am now moved in to my new room in graduate school … cycloadducts from forming with UV light, but then again, I?m no expert in heterocycle photochemistryPosted in The Futile Cycle ( 31 links from 16 sites) [...]

  3. Ian Says:
    September 5th, 2007 at 10:21 pm

    Just as a quick addendum that you probably already know (but it didn’t seem to be mentioned in the site you linked to) — the catastrophic mutatgenesis attack is not unique to HIV; it applies to any virus that replicates as a quasispecies, even those that have relatively low mutation rates. The theory (”error catastrophe”) dates back some twenty years (I think first described in 1988, in a paper that I haven’t read myself: M. Eigen, Sequence space and quasispecies distribution In: E. Domingo, J.J. Holland and P. Ahlquist, Editors, RNA Genetics, CRC, Boca Raton (1988), and then more recently in a paper I have read, M. Eigen, Error catastrophe and antiviral strategy, Proc. Natl. Acad. Sci. U.S.A. 99 (2002), pp. 13374–13376.)

    It’s also been tested experimentally, in a very nice paper from Raul Andino’s lab:
    Virus Research (2005) 107:173-181
    Ribavirin and lethal mutagenesis of poliovirus: molecular mechanisms, resistance and biological implications
    Marco Vignuzzi, Jeffrey K. Stone and Raul Andino

    The conclusion there is that poliovirus, at least (and perhaps many if not all of these quasispecies viruses) normally lives on the edge of error catastrophe, and it doesn’t take much of an increase in the error rate to shove it over the edge into oblivion.

  4. Eric Says:
    September 6th, 2007 at 8:21 am

    I didn’t realize that the theory had been proposed and tested in other systems, but it’s really neat that it does seem to work. I hadn’t realized that most viruses had such a high mutation rate relative to the edge of error catastrophe; I’d just assumed that because everyone made such a big deal about HIV’s quick development of drug resistance and its high mutation rate, that being as close to the edge as HIV wasn’t that common.

  5. Ben Says:
    September 6th, 2007 at 1:04 pm

    I thought Nowak pointed out that most organisms are on the edge of error catastrophe…

  6. Ian Says:
    September 6th, 2007 at 8:45 pm

    because everyone made such a big deal about HIV’s quick development of drug resistance and its high mutation rate, that being as close to the edge as HIV wasn’t that common.

    The rapid development of drug resistance is far from unique to HIV. For example, from the Andino paper —

    Based on the recent identification of ribavirin resistant viruses, what is the likelihood of resistance to lethal mutagenic agents? … by gradually increasing concentrations of ribavirin, a ribavirin-resistant population was achieved within nine passages. This study suggests that at higher concentrations, viral escape is not possible. However, it is important to note that these passages were initiated from a virus clone.

    In our hands, ribavirin resistant mutants dominated the population after only five passages in high concentrations of ribavirin (400 and 600 μM) …

  7. David Says:
    October 24th, 2007 at 6:57 pm

    I’m wondering what the effect will be not on cellular DNA, but on mitochondrial DNA. Mito DNA is more like prokaryotic than eukaryotic DNA and thus has more primitive repair mechanisms. They are (although I haven’t done the research) somewhere between HIV’s poor copying/editing skills and nuclear cellular DNA’s expert proofreaders. I wonder if the “damage” to mitochondria or cellular DNA from the putative drug of this company will be worse than the genetic effects of HIV caused by insertions of viral reverse transcripted DNA.

    An interview with someone from the company stated “Genotoxicity depends on how much of the drug is incorporated by human DNA polymerase, and how much of it is excised [cut out]. In the case of human DNA in the nucleus of cells, KP-1461 is very poorly incorporated — a log [about 10 fold] less than any of the other nucleoside analogs.” http://www.thebodypro.com/content/art43529.html?mtrk=3485014 That’s promising. However, there’s no mention in the article of the impact to mitochondria.

  8. Eric Says:
    October 24th, 2007 at 8:42 pm

    There is some indication that AZT, at high dosage, may have some effect on muscles, where mitochondria are in high numbers, but I don’t know enough of the literature to say how much for sure. I do know that there are some HIV/AIDS deniers who use this fact to falsely claim that antiretrovirals are what actually cause AIDS.

  9. tom Says:
    November 9th, 2007 at 12:39 pm

    Data on Novel Approach in HIV Treatment Presented at ACCP
    KANSAS CITY, Mo. (Oct. 15, 2007) -

    A new approach to HIV treatment designed to increase the rate of HIV mutations and lead to collapse of the viral population is moving into proof-of-concept studies. KP-1461 (Koronis Pharmaceuticals, Inc., Redmond, Wash.) is generally safe and well tolerated when administered at multiple doses according to data presented at the American College of Clinical Pharmacy’s 2007 Annual Meeting in Denver. This novel approach to treating HIV could profoundly alter the prevailing pharmaceutical economics in today’s $9 billion U.S. market for HIV drugs.

    “KP-1461 represents a completely new approach to treating HIV,” said Patrick G. Clay, Pharm.D., associate professor of pharmacology and director of the Dybedal Clinical Research Center. “Unlike approved HIV treatments that work by inhibiting the growth of HIV, KP-1461 is designed to induce mutations that degrade viral fitness and lead to viral collapse.”

    Conventional antiretroviral agents that have profoundly altered the morbidity and mortality rates in persons infected with HIV work by inhibiting key viral enzymes. The most recently approved drugs block viral entry into uninfected cells or stop the virus from replicating after it enters the cell. These two approaches remain effective as long as the patient maintains a continuous, lifelong drug administration or until the virus develops. While collectively responsible for significantly improved survival, current drug mechanisms do not allow consideration of viral eradication.

    KP-1461’s approach is to push the viral population to a point of error catastrophe and collapse through the process of Viral Decay AccelerationTM (VDA).

    VDA works by inducing errors during the replication of the virus. While the virus is already prone to make errors, KP-1461 introduces additional errors leading to so-called error catastrophe and viral population collapse. The prospect of inducing viral population collapse has renewed consideration of viral eradication.

    In repeated in vitro studies, KP-1461 has demonstrated irreversible viral extinction. Results of Phase 1 studies show that treatment with KP-1461 is generally safe and well tolerated when given for two weeks to people who have been infected with HIV. Most of the side effects seen in this study were mild to moderate and no patients stopped the study due to side effects. Though these studies did not expect to see any affect on the virus, trends in the amount of virus in the blood and how well the virus was functioning after being exposed to KP-1461 were encouraging.

    KP-1461 is currently being studied in the next phase of drug discovery. A Phase 2a trial is currently underway to evaluate the safety, efficacy and tolerability of KP-1461 when administered to treatment-experienced HIV patients. The study is ongoing at 30 HIV-research specialty centers in the United States, including Kansas City University of Medicine and Biosciences’ Dybedal Clinical Research Center, under the direction of Dr. Clay.

Leave a Reply